Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

NEJM EvidAug 25, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)

Meagan A Jacoby, David H Spencer, Feng Gao et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II multicenter trial evaluated the impact of leukemia-associated mutation (LAM) clearance on relapse-free survival (RFS) in 100 patients aged 18-60 with intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1). Patients achieving LAM clearance had a median RFS of 33.1 months, significantly longer than the historical cohort's 11.7 months (P=0.015).

Key findings

  • Patients with complete LAM clearance had a median RFS of 33.1 months.
  • Historical cohort had a median RFS of 11.7 months.
  • Statistical significance was noted with P=0.015.
  • The study supports further randomized trials to evaluate this consolidation strategy.

Why it matters

The findings suggest that monitoring LAM clearance could guide consolidation therapy decisions in intermediate-risk AML, potentially improving patient outcomes and informing future treatment protocols.

Source

PubMed · PMID 42640163

Published in NEJM Evid. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.